🇺🇸 FDA

Intelligence · Patent portfolio

Sarepta Therapeutics Patents

Full USPTO pharma patent portfolio for Sarepta Therapeutics — grant dates, expiration, and drug cross-links.

Patents
102
Expiring ≤24m
0

Quick answer

Sarepta Therapeutics has 102 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

Page 1 of 3

  1. US 12377150

    Exon skipping oligomer conjugates for muscular dystrophy

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12370261

    Chimeric peptides for antisense delivery

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12286630

    Treatment methods for muscular dystrophy

    Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12239715

    Peptide oligonucleotide conjugates

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12168059

    Trimeric peptides for antisense delivery

    Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12139709

    Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene

    Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12138312

    Cell-penetrating peptides for antisense delivery

    Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12121532

    Modified antisense oligomers for exon inclusion in spinal muscular atrophy

    Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12104163

    Adeno-associated virus vectors for treatment of Rett syndrome

    Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11932851

    Exon skipping compositions for treating muscular dystrophy

    Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11925675

    Systemic delivery of adeno-associated virus vector expressing gamma-sarcoglycan and the treatment of muscular dystrophy

    Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11911403

    Antisense-induced exon exclusion in type VII collagen

    Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11732259

    Peptide oligonucleotide conjugates

    Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11674139

    Oligonucleotides for treating expanded repeat diseases

    Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11672871

    Peptide oligonucleotide conjugates

    Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11642364

    Exon skipping oligomer conjugates for muscular dystrophy

    Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11555189

    Antisense oligomer compounds

    Expires Mon Jan 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11491238

    Exon skipping oligomer conjugates for muscular dystrophy

    Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11395855

    Exon skipping oligomer conjugates for muscular dystrophy

    Expires Mon Jul 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11382981

    Exon skipping oligomer conjugates for muscular dystrophy

    Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11338041

    Exon skipping oligomer conjugates for muscular dystrophy

    Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11236338

    Antisense-induced exon2 inclusion in acid alpha-glucosidase

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11236329

    Compound and method for treating myotonic dystrophy

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11225662

    Peptide oligonucleotide conjugates

    Expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11208655

    Functionally-modified oligonucleotides and subunits thereof

    Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11097011

    Peptide oligonucleotide conjugates

    Expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11071749

    Oligonucleotide analogues targeting human LMNA

    Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11060089

    Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene

    Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11020417

    Methods and compounds for treatment of lymphocyte-related diseases and conditions

    Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11015200

    Antisense-induced exon exclusion in myostatin

    Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11000600

    Exon skipping oligomer conjugates for muscular dystrophy

    Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10927378

    Compound and method for treating myotonic dystrophy

    Expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10905709

    Modified antisense oligomers for exon inclusion in spinal muscular atrophy

    Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10905782

    Compositions for enhancing transport of molecules into cells

    Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10907154

    Exon skipping compositions for treating muscular dystrophy

    Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10888578

    Exon skipping oligomer conjugates for muscular dystrophy

    Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10849917

    Antisense-induced exon exclusion in type VII collagen

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10781450

    Antisense molecules and methods for treating pathologies

    Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10765760

    Exon skipping oligomer conjugates for muscular dystrophy

    Expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10758629

    Exon skipping oligomer conjugates for muscular dystrophy

    Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10760078

    Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups

    Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10675356

    Peptide oligonucleotide conjugates

    Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10626396

    Antisense composition and method for treating muscle atrophy

    Expires Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10577605

    Induced exon inclusion in spinal muscle atrophy

    Expires Mon Feb 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10533174

    Splice-region antisense composition and method

    Expires Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10487326

    Peptide oligonucleotide conjugates

    Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10479996

    Antisense antiviral compound and method for treating ss/RNA viral infection

    Expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10364431

    Compositions for treating muscular dystrophy

    Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Sarepta Therapeutics have?

102 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Sarepta Therapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.